



# Novel bifunctional thiourea–ammonium salt catalysts derived from amino acids: application to highly enantio- and diastereoselective aza-Henry reaction

Hong-Yu Wang<sup>a</sup>, Zhuo Chai<sup>b</sup>, Gang Zhao<sup>a,b,\*</sup>

<sup>a</sup> Department of Chemistry, University of Science and Technology of China, Hefei 230026, Anhui, China

<sup>b</sup> Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese Academy of Science, 345 Lingling Lu, Shanghai 200032, China

## ARTICLE INFO

### Article history:

Received 19 March 2013

Received in revised form 12 April 2013

Accepted 17 April 2013

Available online 20 April 2013

### Keywords:

Asymmetric catalysis

Phase-transfer catalyst

Amino acid

Aza-Henry reaction

Thiourea–ammonium

## ABSTRACT

The development of new efficient and easily accessible catalysts has been one of the focuses in asymmetric phase-transfer catalysis. In this paper, a novel class of chiral bifunctional thiourea–ammonium phase-transfer catalysts were synthesized from commercially available  $\alpha$ -amino acids. The structural modularity of these catalysts permits facile tunings to achieve optimum results, which was demonstrated in catalyzing the aza-Henry reaction with excellent enantioselectivities (up to 99.5% ee) and diastereoselectivities (up to >25:1 dr).

© 2013 Elsevier Ltd. All rights reserved.

## 1. Introduction


As an inexpensive and readily accessible chiral source, chiral  $\alpha$ -amino acids have attracted much interest as an arsenal for the development of diverse organocatalysts, which have found extensive applications in asymmetric synthesis.<sup>1</sup> One of the recent remarkable advances in this field is the development of novel bifunctional or multifunctional organocatalysts based on simple chiral acyclic  $\alpha$ -amino acids.<sup>2</sup> Representative catalysts including primary–secondary diamines,<sup>3</sup> tertiary amine–thioureas,<sup>4</sup> and aminophosphines<sup>5</sup> have been successfully applied to a variety of reactions. The success of these catalysts is closely related to the two obvious advantages endowed with chiral  $\alpha$ -amino acids as a chiral pool: ready availability at affordable costs and modular structures enabling facile fine tunings.

The catalytic asymmetric phase-transfer catalysis has been well-established as one of the major commonly utilized methodology for the synthesis of kinds of organic compounds.<sup>6</sup> In this realm, while most catalysts are derived from cinchona alkaloids<sup>6g,h</sup> (Scheme 1, I), chiral binols<sup>6i,j</sup> (Scheme 1, II) or chiral guanidines<sup>6k</sup> (Scheme 1, III) with great success achieved, the development and applications of

novel catalytic systems are still of key importance for the continuing advancement of this methodology.

Our group have focused on the development of novel bifunctional chiral organocatalysts from simple acyclic  $\alpha$ -amino acid.<sup>7</sup> Bi- or multifunctionality, especially with an emphasis on H-bond interaction, has been one of the key concepts with great success in the design of new organocatalysts for asymmetric catalysis.<sup>8</sup> However, the application of such a concept in the development of new chiral phase-transfer catalysts has been still rather limited,<sup>9</sup> especially in the case of amino acid-based phase-transfer catalysts. Notably, Ooi and co-workers have developed a new family of chiral 1,2,3-triazoliums using  $\alpha$ -amino acids over 10 steps, and applied them to some reactions with excellent results.<sup>10</sup> Our previous good results obtained with the bifunctional primary–tertiary diamine catalysts have inspired us to the development of structurally-related novel bifunctional ammonium salt phase-transfer catalysts (Fig. 1).<sup>11</sup> The highly modular structures of these bifunctional catalysts allow for easy fine tunings at different positions for efficiency improvement. To demonstrate the great potential of these new catalysts for applications in asymmetric phase-transfer catalysis, we applied them to catalyze the aza-Henry reaction as a model, which is an important method for the synthesis of numerous biologically active compounds and building blocks of natural products, such as vicinal diamines and  $\alpha$ -amino acids.<sup>12</sup>

\* Corresponding author. Tel.: +86 21 54925182; fax: +86 21 64166128; e-mail address: [zhaog@mail.sioc.ac.cn](mailto:zhaog@mail.sioc.ac.cn) (G. Zhao).



Scheme 1. Chiral quaternary ammonium catalysts (anions are omitted).




Fig. 1. Design and synthesis of bifunctional thiourea–ammonium salt catalysts.

## 2. Results and discussion

The *N*-Boc imines used in the aza-Henry reaction for this study were in situ generated from amidosulfones.<sup>9c,f,13</sup> The results of the optimization of the reaction condition parameters, such as screenings of catalysts (Fig. 2), solvents were listed in Table 1. We chose the reaction between amidosulfone **2a** and nitromethane **4a** in the presence of 5 equiv of KOH at  $-20\text{ }^{\circ}\text{C}$  in toluene as a model reaction for catalyst evaluation (entries 1–8). Firstly, catalysts **1a–e** derived from *L*-leucine and *L*-isoleucine with different substitutions at the ammonium centre ( $R^1$ ) and thiourea moieties ( $R^2$ ) were tested (entries 1–5). The enantioselectivity of the reaction seemed susceptible to changes on both sites and a suitable combination of the substituent groups was identified as in the catalyst **1d** ( $R^1=4\text{-BrC}_6\text{H}_4$ ,  $R^2=4\text{-NO}_2\text{C}_6\text{H}_4$ , entry 4). Subsequent examination of the chiral backbones of these ammonium salts revealed a superior catalyst **1f** derived from *tert*-butyl leucine (entry 6). The ensuing investigation of solvent effect indicated that this reaction gave a higher level of enantiocontrol in  $\text{CH}_2\text{Cl}_2$  (entry 9), with the best ee value (92%) obtained at  $-30\text{ }^{\circ}\text{C}$  (entry 13). The use of weaker bases led to inferior results (entries 14–17).

tolerated in the reaction to give the desired products in high yields and with good to excellent enantioselectivities (entries 1–9). While substrates with electron-donating groups on the benzene ring are favoured over those with electron-withdrawing ones in terms of yield and ee value, the influence of the positions of these substituents seemed negligible. However, a significant drop in enantioselectivity was observed with the aliphatic substrate **2j**, while the yield remained excellent (entry 10). To our delight, the employment of nitroethane **4b** also provided excellent yields and ee values, although the dr values were sensitive to the substitution changes of the aryl groups, fluctuating between moderate to excellent (entries 11 and 13–15). The 1-nitropropane **4c** bearing a longer alkyl chain also gave an excellent yield, high ee value and a moderate dr value (entry 12). Notably, the reaction between **2a** and nitromethane **4a** could be performed on a gram-scale with only a slight decrease in the yield and enantioselectivity (entry 16).

To get some insights into the catalytic mechanism of the reaction, we performed two control experiments to test the role of the H-bond sites (the thiourea moiety) and the quaternary ammonium centre of the bifunctional phase-transfer catalysts (Scheme 2). When we employed the thiourea-tertiary amine cata-






Fig. 2. Catalysts screened in this study.

Under these optimized reaction conditions, we then surveyed the substrate scope of this reaction with different amidosulfones and nitroalkanes (Table 2). With nitromethane **4a**, in general, various amidosulfones with diverse aromatic groups ( $R_x$ ) were well

lyst **1l**, which lacks the quaternary ammonium centre compared to **1b** (Table 1, entry 1), the enantioselectivity slumped to 3% ee, though the yield was excellent. Similarly, the use of catalyst **1m** with one blocked H-donor site also gave much inferior results.

**Table 1**  
Screening of phase-transfer catalysts<sup>a</sup>


| Entry           | Catalyst  | Solvent                         | Base                            | Yield <sup>b</sup> (%) | ee <sup>c</sup> (%) |
|-----------------|-----------|---------------------------------|---------------------------------|------------------------|---------------------|
| 1               | <b>1a</b> | Toluene                         | KOH                             | 85                     | 75                  |
| 2               | <b>1b</b> | Toluene                         | KOH                             | 90                     | 77                  |
| 3               | <b>1c</b> | Toluene                         | KOH                             | 80                     | 62                  |
| 4               | <b>1d</b> | Toluene                         | KOH                             | 81                     | 80                  |
| 5               | <b>1e</b> | Toluene                         | KOH                             | 73                     | 65                  |
| 6               | <b>1f</b> | Toluene                         | KOH                             | 78                     | 87                  |
| 7               | <b>1g</b> | Toluene                         | KOH                             | 85                     | 73                  |
| 8               | <b>1h</b> | Toluene                         | KOH                             | 80                     | 80                  |
| 9               | <b>1f</b> | CH <sub>2</sub> Cl <sub>2</sub> | KOH                             | 85                     | 90                  |
| 10              | <b>1f</b> | CHCl <sub>3</sub>               | KOH                             | 80                     | 70                  |
| 11              | <b>1f</b> | PhCF <sub>3</sub>               | KOH                             | 88                     | 79                  |
| 12              | <b>1f</b> | TBME                            | KOH                             | 85                     | 70                  |
| 13 <sup>d</sup> | <b>1f</b> | CH <sub>2</sub> Cl <sub>2</sub> | KOH                             | 94                     | 92                  |
| 14 <sup>d</sup> | <b>1f</b> | CH <sub>2</sub> Cl <sub>2</sub> | NaOH                            | 85                     | 84                  |
| 15 <sup>d</sup> | <b>1f</b> | CH <sub>2</sub> Cl <sub>2</sub> | Cs <sub>2</sub> CO <sub>3</sub> | 40                     | 56                  |
| 16 <sup>d</sup> | <b>1f</b> | CH <sub>2</sub> Cl <sub>2</sub> | K <sub>2</sub> CO <sub>3</sub>  | Trace                  | nd                  |
| 17 <sup>d</sup> | <b>1f</b> | CH <sub>2</sub> Cl <sub>2</sub> | Na <sub>2</sub> CO <sub>3</sub> | Trace                  | nd                  |


<sup>a</sup> Unless otherwise noted, the reaction was carried out with **2a** (0.2 mmol) and CH<sub>3</sub>NO<sub>2</sub> (1.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub>.<sup>b</sup> Yield of the isolated product.<sup>c</sup> Determined by HPLC analysis.<sup>d</sup> At -30 °C.**Table 2**  
Substrate scope study of the asymmetric aza-Henry reaction<sup>a</sup>


| Entry | <b>2</b> (R <sub>x</sub> )                                   | <b>4</b> (R <sub>y</sub> ) | <b>3</b>  | Yield <sup>b</sup> (%) | ee <sup>c</sup> (%) | dr <sup>d</sup> |
|-------|--------------------------------------------------------------|----------------------------|-----------|------------------------|---------------------|-----------------|
| 1     | <b>2a</b> (Ph)                                               | <b>4a</b> (H)              | <b>3a</b> | 94                     | 92                  | —               |
| 2     | <b>2b</b> (4-FC <sub>6</sub> H <sub>4</sub> )                | <b>4a</b> (H)              | <b>3b</b> | 80                     | 89                  | —               |
| 3     | <b>2c</b> (4-MeC <sub>6</sub> H <sub>4</sub> )               | <b>4a</b> (H)              | <b>3c</b> | 92                     | 93                  | —               |
| 4     | <b>2d</b> (4-CF <sub>3</sub> C <sub>6</sub> H <sub>4</sub> ) | <b>4a</b> (H)              | <b>3d</b> | 85                     | 89                  | —               |
| 5     | <b>2e</b> (4-MeOC <sub>6</sub> H <sub>4</sub> )              | <b>4a</b> (H)              | <b>3e</b> | 90                     | 94                  | —               |
| 6     | <b>2f</b> (3-MeOC <sub>6</sub> H <sub>4</sub> )              | <b>4a</b> (H)              | <b>3f</b> | 90                     | 96                  | —               |
| 7     | <b>2g</b> (2-MeOC <sub>6</sub> H <sub>4</sub> )              | <b>4a</b> (H)              | <b>3g</b> | 98                     | 94                  | —               |
| 8     | <b>2h</b> (1-Naphthyl)                                       | <b>4a</b> (H)              | <b>3h</b> | 99                     | 91                  | —               |
| 9     | <b>2i</b> (2-Furyl)                                          | <b>4a</b> (H)              | <b>3i</b> | 80                     | 88                  | —               |
| 10    | <b>2j</b> (PhCH <sub>2</sub> CH <sub>2</sub> )               | <b>4a</b> (H)              | <b>3j</b> | 98                     | 68                  | —               |
| 11    | <b>2a</b> (Ph)                                               | <b>4b</b> (Me)             | <b>3k</b> | 99                     | 96                  | 20:1            |
| 12    | <b>2a</b> (Ph)                                               | <b>4c</b> (Et)             | <b>3l</b> | 99                     | 89                  | 8:1             |
| 13    | <b>2b</b> (4-FC <sub>6</sub> H <sub>4</sub> )                | <b>4b</b> (Me)             | <b>3m</b> | 99                     | 99                  | 6:1             |
| 14    | <b>2d</b> (4-MeOC <sub>6</sub> H <sub>4</sub> )              | <b>4b</b> (Me)             | <b>3n</b> | 99                     | 97                  | >25:1           |
| 15    | <b>2f</b> (3-MeOC <sub>6</sub> H <sub>4</sub> )              | <b>4b</b> (Me)             | <b>3o</b> | 99                     | 99.5                | 9:1             |
| 16    | <b>2a</b> (Ph)                                               | <b>4a</b> (H)              | <b>3a</b> | 92                     | 89                  | —               |

<sup>a</sup> Unless otherwise noted, all reactions were carried out with **2** (0.2 mmol) and **4** (1.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) catalyzed by **1f** (5 mol %) at -30 °C.<sup>b</sup> Isolated yield.<sup>c</sup> Determined by <sup>1</sup>H NMR or chiral HPLC analysis.<sup>d</sup> The reaction was run on a gram scale of **2a** (1.8 g, 5.2 mmol).

These results suggested that both the quaternary ammonium centre and the double H-bond donors were crucial for the asymmetric induction.

On the basis of our experiment results and previous relevant studies,<sup>9c</sup> we proposed a possible transition state model to rationalize the stereochemical results of the reaction (Fig. 3) (see the SD for more details). It is assumed that the in situ generated imine might have H-bonding interaction with the thiourea moiety of the catalyst, while the nitro group anion of the nucleophile

**Scheme 2.** Control experiments for mechanistic study.

nitromethane would be directed by the quaternary ammonium centre by the Coulomb force (static interaction). Such an assembly would make the *Re*-face attack of the nucleophile more favourable.

To extend the utility of this reaction, we studied some useful transformations of the products **3** (Scheme 3). Firstly, we developed a four-step transformation of the product **3a** to the chiral compound **5** in high yields (56% over four steps) while maintaining the optical purity of the product. Using a known method, compound **5** could be transformed into taurine,<sup>14</sup> which belongs to a family of molecules with useful pharmaceutical values. Then we achieved the conversion of **3k** into chiral amine **6**,<sup>15</sup> which is an important building block in organic synthesis,<sup>16</sup> by a radical process to get rid of the nitro group. The stereochemical integrity was also well maintained in this process.

### 3. Conclusion

In conclusion, we have developed a novel family of bifunctional (thio)urea–ammonium salts as chiral phase-transfer catalysts based on simple acyclic α-amino acids. These new catalysts demonstrated high efficiency in the aza-Henry reaction between amidosulfones and nitroalkanes, in which H-bond and ammonium salts are crucial to achieve excellent enantioselectivities and diastereoselectivities. Highly modular structures as well as their ready accessibility render them promising catalysts in organic catalysis. Efforts towards a deep understanding of the reaction mechanism as well as the application of these catalysts to other relevant reactions are currently underway in our laboratories.

### 4. Experimental

#### 4.1. General

The <sup>1</sup>H NMR spectra were recorded on a Bruker (400 MHz). All chemical shifts (δ) were given in parts per million. Data were reported as follows: chemical shift, integration, multiplicity (s=single, d=doublet, t=triplet, q=quartet, br=broad, m=multiplet) and coupling constants hertz (Hz). <sup>13</sup>C NMR spectra were recorded on a DPX-400 (400 MHz). Flash column chromatography was performed using H silica gel. For thin-layer chromatography (TLC), silica gel plates (HSGF 254) were used and compounds were visualized by irradiation with UV light. Analytical high performance liquid chromatography (HPLC) was carried out on SHIMADZU equipment using chiral columns. Melting points were determined on an SGW X-4 melting point and were uncorrected. Optical rotations were measured on a JASCO P-1010 Polarimeter at λ=589 nm. IR spectra were recorded on a Perkin–Elmer 983G instrument. Mass spectra analysis was performed on API 200 LC/MS system (Applied Biosystems Co. Ltd.).





Fig. 3. A possible transition state.



All reagents purchased from commercial sources were used as sold and purified by standard techniques. All starting amido-sulfones were synthesized by condensation of the corresponding aldehyde with *tert*-butyl carbamate and benzenesulfonic acid sodium salt mediated by formic acid in an aqueous media.

#### 4.2. Typical procedure for the preparation of bifunctional ammonium salts **1**

With a modified method according to the Ref. 4: to a stirred solution of Boc-protected  $\alpha$ -amino acid (2.0 mmol) in  $\text{CH}_2\text{Cl}_2$  (10.0 mL) were added HBTU (3.0 mmol) and DIPEA (4.0 mmol) at 0 °C. Then dimethylamine (2 mmol) was added and the reaction mixture was vigorously stirred at room temperature and monitored by TLC. After 2 h, the resulting solution was poured into 100 mL of  $\text{H}_2\text{O}$ , the organic layer was separated, washed with 1.0 M HCl, and dried over  $\text{Na}_2\text{SO}_4$ . The solvent was removed under reduced pressure and the crude product was dissolved into a mixture of TFA (4.0 mmol)/ $\text{CH}_2\text{Cl}_2$  (20 mL), and the resulting mixture was stirred at room temperature overnight. The mixture was extracted by water firstly and then the combined aqueous layer was basified with satd aq  $\text{NaHCO}_3$  solution, which was then extracted with  $\text{CH}_2\text{Cl}_2$ . The combined organic phases were dried over anhydrous  $\text{Na}_2\text{SO}_4$ , and concentrated under reduced pressure. After that, the crude product was added dropwise into

a suspension of  $\text{LiAlH}_4$  (6.0 mmol) in dried THF (30 mL) at 0 °C, when finished, the mixture was stirred at 75 °C for 24 h before being carefully quenched by sequential addition of water until the stop of gas evolution. Then anhydrous  $\text{Na}_2\text{SO}_4$  was added into the mixture, then the mixture was filtered through silica gel and the filtrate was concentrated under reduced pressure. The crude product was then dissolved into  $\text{CH}_2\text{Cl}_2$ , and the isothiocyanate or isocyanate was added into this solution, and stirred overnight. Then the solvent was removed in vacuo to afford the crude product, which could be used directly in the next step. The crude product was dissolved in a solution of  $\text{CH}_3\text{CN}$  (5.0 mL)/R'Br (2 equiv), and the resulting mixture was stirred at room temperature overnight and monitored by TLC. After completion of the reaction, the solvent was removed under reduced pressure using a rotary evaporator and the residue was purified by silica gel chromatography ( $\text{CH}_2\text{Cl}_2$ ,  $\text{CH}_2\text{Cl}_2$ /methanol as the eluent) to afford the desired products **1**.

**4.2.1. (S)-N-Benzyl-2-(3-(3,5-bis(trifluoromethyl)phenyl)thioureido)-N,N,4-trimethylpentan-1-ammonium bromide (1a).** Yield: 60%; yellow solid;  $[\alpha]_D^{26} = -20.6$  (c 3.5,  $\text{CHCl}_3$ ); mp=107–109 °C; IR (neat): 2958, 1552, 1511, 1329, 1255, 730;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  10.39 (s, 1H), 9.34–9.32 (d,  $J=8.0$  Hz, 1H), 8.12–8.10 (d,  $J=8$  Hz, 2H), 8.03–8.00 (d,  $J=12$  Hz, 2H), 7.56–7.53 (m, 1H), 7.49–7.48 (d,  $J=4.0$  Hz, 4H), 5.55–5.48 (m, 1H), 4.87–4.84 (d,  $J=12.0$  Hz, 1H),

4.70–4.67 (d,  $J=12.0$  Hz, 1H), 4.35–4.29 (m, 1H), 3.27–3.23 (br, 7H), 1.85–1.76 (m, 2H), 1.38–1.31 (m, 1H), 1.07–1.05 (d,  $J=8$  Hz, 3H), 0.99–0.97 (d,  $J=8$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  180.42, 145.81, 142.95, 132.88, 131.19, 129.44, 128.90, 128.81, 128.62, 126.56, 124.22, 121.23, 69.68, 68.45, 51.20, 50.21, 47.75, 43.86, 24.33, 23.14, 22.66; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{22}\text{H}_{31}\text{N}_4\text{O}_2\text{S}$ ) requires 415.2168, found 415.2171.

4.2.2. (*S*)-2-(3-(3,5-Bis(trifluoromethyl)phenyl)thioureido)-*N*-(4-bromobenzyl)-*N,N*,4-trimethylpentan-1-ammonium bromide (**1b**). Yield: 70%; white solid;  $[\alpha]_D^{26} -30.5$  (c 2.0,  $\text{CHCl}_3$ ); mp=113–116 °C; IR (neat): 2960, 1593, 1544, 1473, 1383, 1133, 885, 738;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.80 (s, 1H), 8.82–8.79 (d,  $J=8.0$  Hz, 1H), 8.24 (s, 2H), 7.59–7.55 (t,  $J=8.0$  Hz, 3H), 7.39–7.37 (d,  $J=8.0$  Hz, 2H), 5.56–5.48 (m, 1H), 4.95–4.92 (d,  $J=12.0$  Hz, 1H), 4.69–4.66 (d,  $J=12.0$  Hz, 1H), 4.51–4.44 (dd,  $J=8.0$ , 4.0 Hz, 1H), 3.35–3.31 (d,  $J=12.0$  Hz, 1H), 3.23 (s, 6H), 1.89–1.82 (m, 1H), 1.81–1.74 (m, 1H), 1.40–1.43 (m, 1H), 1.05–1.04 (d,  $J=4.0$  Hz, 3H), 0.97–0.96 (d,  $J=4.0$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  181.06, 140.74, 134.45, 134.40, 132.72, 131.73, 131.44 (q,  $J_{\text{C-F}}=33.0$  Hz), 130.62, 130.57, 126.06, 125.43, 124.58 (q,  $J_{\text{C-F}}=279.0$  Hz), 123.02, 121.64, 117.66, 70.07, 67.35, 51.04, 50.34, 48.15, 43.84, 24.37, 23.06, 22.63; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{24}\text{H}_{29}\text{BrF}_6\text{N}_3\text{S}$ ) requires 584.1170, found 584.1167.

4.2.3. (*S*)-2-(3-(3,5-Bis(trifluoromethyl)phenyl)ureido)-*N*-(4-bromobenzyl)-*N,N*,4-trimethylpentan-1-ammonium bromide (**1c**). Yield: 65%; white solid;  $[\alpha]_D^{26} -77.8$  (c 1.0,  $\text{CHCl}_3$ ); mp=106–107 °C; IR (neat): 2962, 1698, 1573, 1474, 1277, 1131, 881, 738, 703;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  9.31 (s, 1H), 8.03 (s, 2H), 7.61–7.59 (d,  $J=8.0$  Hz, 2H), 7.50–7.48 (d,  $J=8.0$  Hz, 1H), 7.44 (s, 2H), 7.42 (s, 1H), 4.91–4.88 (d,  $J=12.0$  Hz, 1H), 4.77–4.74 (d,  $J=12.0$  Hz, 1H), 4.58–4.51 (m, 1H), 4.24–4.18 (br, 1H), 3.34–3.31 (d,  $J=12.0$  Hz, 1H), 3.27 (s, 3H), 3.23 (s, 3H), 1.85–1.81 (m, 1H), 1.78–1.70 (m, 1H), 1.29–1.22 (m, 1H), 0.96–0.93 (br, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  155.4, 140.9, 134.4, 132.7, 131.9 (q,  $J_{\text{C-F}}=33.0$  Hz), 126.1, 125.3, 124.5 (q,  $J_{\text{C-F}}=271.0$  Hz), 117.8, 115.1, 69.3, 67.8, 50.8, 50.2, 43.9, 43.2, 24.2, 23.0, 21.4; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{24}\text{H}_{29}\text{BrF}_6\text{N}_3\text{O}$ ) requires 568.1398, found 584.1383.

4.2.4. (*S*)-*N*-(4-Bromobenzyl)-*N,N*,4-trimethyl-2-(3-(4-nitrophenyl)thioureido)pentan-1-ammonium bromide (**1d**). Yield: 77%; yellow solid;  $[\alpha]_D^{26} -54.5$  (c 0.5,  $\text{CHCl}_3$ ); mp=111–114 °C; IR (neat): 2960, 1593, 1544, 1383, 1277, 1133, 885, 847;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  10.26 (s, 1H), 9.34–9.31 (d,  $J=8.0$  Hz, 1H), 8.14–8.12 (d,  $J=8.0$  Hz, 2H), 8.02–8.00 (d,  $J=8.0$  Hz, 2H), 7.65–7.63 (d,  $J=8.0$  Hz, 2H), 7.40–7.38 (d,  $J=8.0$  Hz, 2H), 5.54–5.47 (br, 1H), 4.95–4.91 (d,  $J=12.0$  Hz, 1H), 4.70–4.67 (d,  $J=12.0$  Hz, 1H), 4.40–4.34 (m, 1H), 3.32–3.26 (br, 6H), 3.20–3.18 (d,  $J=8.0$  Hz, 1H), 1.83–1.75 (m, 2H), 1.37–1.30 (m, 1H), 1.06–1.05 (d,  $J=4.0$  Hz, 3H), 0.99–0.98 (d,  $J=4.0$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  180.38, 145.54, 143.16, 134.44, 132.81, 131.69, 130.58, 126.17, 125.47, 125.03, 124.29, 124.25, 121.38, 121.29, 69.83, 67.44, 51.17, 50.41, 47.75, 43.93, 24.38, 23.14, 22.63; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{22}\text{H}_{30}\text{BrN}_4\text{O}_2\text{S}$ ) requires 493.1273, found 493.1283.

4.2.5. (2*S*,3*S*)-*N,N*,3-Trimethyl-*N*-(4-nitrobenzyl)-2-(3-(4-nitrophenyl)thioureido)pentan-1-ammonium bromide (**1e**). Yield: 80%; yellow solid;  $[\alpha]_D^{26} -18.0$  (c 0.5,  $\text{CHCl}_3$ ); mp=119–121 °C; IR (neat): 2964, 1524, 1329, 1251, 1110, 852, 732;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$  11.19 (s, 1H), 9.52–9.49 (d,  $J=8.0$  Hz, 1H), 8.31–8.29 (d,  $J=8.0$  Hz, 2H), 8.15–8.12 (d,  $J=8.0$  Hz, 2H), 8.10–8.07 (d,  $J=8.0$  Hz, 2H), 7.85–7.83 (d,  $J=8.0$  Hz, 2H), 5.41–5.35 (m, 1H), 4.93–4.90 (d,  $J=12.0$  Hz, 1H), 4.83–4.80 (d,  $J=12.0$  Hz, 1H), 3.93–3.87 (m, 1H), 3.66–3.63 (d,  $J=12.0$  Hz, 1H), 3.19–3.18 (br, 6H), 1.84–1.79 (m, 1H), 1.58–1.51 (m, 1H), 1.45–1.35 (m, 1H), 1.07–1.05 (d,  $J=8.0$  Hz, 3H), 0.99–0.96 (t,  $J=8.0$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$  180.7, 149.3, 146.2, 142.9, 134.6, 134.1, 129.7, 124.8, 124.2, 124.0, 121.6, 120.7, 117.3, 67.3, 66.8,

62.2, 60.7, 60.5, 40.2, 24.6, 14.4, 11.2; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{22}\text{H}_{30}\text{N}_5\text{O}_4\text{S}$ ) requires 460.2019, found 460.2008.

4.2.6. (*S*)-*N,N*,3,3-Tetramethyl-*N*-(4-bromobenzyl)-2-(3-(4-nitrophenyl)thioureido)butan-1-ammonium bromide (**1f**). Yield: 76%; yellow solid;  $[\alpha]_D^{26} -119.9$  (c 1.0,  $\text{CHCl}_3$ ); mp=112–114 °C; IR (neat): 2963, 1575, 1508, 1330, 1257, 1109, 851, 727;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  10.54 (s, 1H), 9.43–9.40 (d,  $J=12.0$  Hz, 1H), 8.13–8.11 (d,  $J=8.0$  Hz, 2H), 8.05–8.02 (d,  $J=12.0$  Hz, 2H), 7.63–7.61 (d,  $J=8.0$  Hz, 2H), 7.42–7.40 (d,  $J=8.0$  Hz, 2H), 5.26–5.21 (t,  $J=12.0$  Hz, 1H), 4.97–4.93 (d,  $J=16.0$  Hz, 1H), 4.65–4.62 (d,  $J=12.0$  Hz, 1H), 4.41–4.35 (m, 1H), 3.61–3.58 (d,  $J=12.0$  Hz, 1H), 3.25 (s, 3H), 3.18 (s, 3H), 1.13 (s, 9H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  181.20, 145.66, 143.13, 134.55, 132.74, 131.72, 131.71, 130.73, 130.64, 126.11, 125.51, 124.25, 121.26, 67.83, 67.56, 56.35, 50.69, 49.86, 37.15, 26.44; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{22}\text{H}_{30}\text{BrN}_4\text{O}_2\text{S}$ ) requires 493.1273, found 493.1261.

4.2.7. (*S*)-*N*-(4-Bromobenzyl)-*N,N*-dimethyl-2-(3-(4-nitrophenyl)thioureido)-3-phenylpropan-1-ammonium bromide (**1g**). Yield: 70%; yellow solid;  $[\alpha]_D^{26} -53.3$  (c 3.5,  $\text{CHCl}_3$ ); mp=113–116 °C; IR (neat): 2964, 1510, 1329, 1253, 1110, 850;  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{CN}$ )  $\delta$  10.10 (s, 1H), 9.56–9.53 (d,  $J=8.0$  Hz, 1H), 8.14–8.12 (d,  $J=8.0$  Hz, 2H), 8.00–7.98 (d,  $J=8.0$  Hz, 2H), 7.53–7.51 (d,  $J=8.0$  Hz, 2H), 7.36–7.30 (br, 5H), 7.17–7.15 (d,  $J=8.0$  Hz, 2H), 5.64–5.56 (br, 1H), 4.70–4.67 (d,  $J=12.0$  Hz, 1H), 4.51–4.47 (br, 1H), 4.43–4.39 (d,  $J=12.0$  Hz, 1H), 3.32–3.29 (br, 1H), 3.27–3.23 (d,  $J=12.0$  Hz, 1H), 3.07 (br, 4H), 2.97 (s, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  180.0, 145.4, 143.0, 135.7, 134.3, 132.6, 131.6, 130.5, 129.4, 127.5, 126.0, 125.1, 124.3, 121.3, 67.9, 66.3, 51.1, 51.0, 50.2, 40.4; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{25}\text{H}_{28}\text{BrN}_4\text{O}_2\text{S}$ ) requires 527.1116, found 527.1099.

4.2.8. (2*S*,3*S*)-*N*-(4-Bromobenzyl)-*N,N*,3-trimethyl-2-(3-(4-nitrophenyl)thioureido)pentan-1-ammonium bromide (**1h**). Yield: 69%; yellow solid;  $[\alpha]_D^{26} -30.3$  (c 3.5,  $\text{CHCl}_3$ ); mp=105–106 °C; IR (neat): 2964, 1572, 1508, 1328, 1253, 1110, 1013, 851, 734;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  10.32 (s, 1H), 9.39–9.37 (d,  $J=8.0$  Hz, 1H), 8.14–8.12 (d,  $J=8.0$  Hz, 2H), 8.03–8.01 (d,  $J=8.0$  Hz, 2H), 7.63–7.61 (d,  $J=8.0$  Hz, 2H), 7.42–7.39 (d,  $J=8.0$  Hz, 2H), 5.42–5.36 (m, 1H), 4.94–4.91 (d,  $J=12.0$  Hz, 1H), 4.66–4.63 (d,  $J=12.0$  Hz, 1H), 4.42–4.36 (m, 1H), 3.46–3.43 (d,  $J=12.0$  Hz, 1H), 3.24 (s, 3H), 3.19 (s, 3H), 1.57–1.48 (m, 1H), 1.39–1.30 (m, 1H), 1.09 (d,  $J=8.0$  Hz, 3H), 0.99–0.96 (t,  $J=8.0$  Hz, 3H), 0.87–0.82 (m, 1H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  180.47, 145.69, 143.03, 134.56, 132.68, 131.66, 130.58, 126.03, 125.59, 124.26, 121.17, 52.45, 50.71, 50.02, 40.15, 36.82, 36.78, 25.10, 15.10, 11.89; HRMS (ESI): calcd for  $[\text{M}-\text{Br}]^+$  ( $\text{C}_{22}\text{H}_{30}\text{BrN}_4\text{O}_2\text{S}$ ) requires 493.1273, found 493.1289.

### 4.3. Preparation of 1m

To a stirred solution of Boc-protected  $\alpha$ -amino acid (2.0 mmol) in  $\text{CH}_2\text{Cl}_2$  (10.0 mL) were added HBTU (3.0 mmol) and DIPEA (4.0 mmol) at 0 °C. Then dimethylamine (2 mmol) was added and the reaction mixture was vigorously stirred at room temperature and monitored by TLC. After 2 h, the resulting solution was diluted with 100 mL of  $\text{H}_2\text{O}$ , the organic layer was separated, washed with 1.0 M HCl and dried over  $\text{Na}_2\text{SO}_4$ . The solvent was removed under reduced pressure and the crude product was added dropwise into a suspension of  $\text{LiAlH}_4$  (6 mmol) in dried THF (30 mL) at 0 °C. The resulting mixture was stirred at 75 °C for 24 h, and was then carefully quenched by sequential addition of water until the stop of gas evolution. Anhydrous  $\text{Na}_2\text{SO}_4$  was added into the mixture and after filtration through silica gel, the filtrate was concentrated under reduced pressure. The crude product was then dissolved in  $\text{CH}_2\text{Cl}_2$  to form a solution, to which the isothiocyanate was added and followed by stirring overnight. Then the solvent was removed in vacuo to afford the crude product, which was used directly in the next step.

The crude product was dissolved in a solution of 1-bromo-4-(bromomethyl)benzene (2.0 equiv) in CH<sub>3</sub>CN (5.0 mL) and then the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure using a rotary evaporator and the residue was purified by silica gel chromatography (CH<sub>2</sub>Cl<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>/methanol as the eluent) to afford the desired product **1m**.

**4.3.1. (S)-N-(4-Bromobenzyl)-N,N,4-trimethyl-2-(1-methyl-3-(4-nitrophenyl)thioureido)-pentan-1-ammonium bromide (1m).** Yield: 70%; yellow solid;  $[\alpha]_D^{25}$  –33.1 (c 3.5, CHCl<sub>3</sub>); mp=112–115 °C; IR (neat): 2958, 1594, 1510, 1326, 1110, 1074, 854; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.23 (s, 1H), 8.16–8.13 (d, J=12.0 Hz, 2H), 7.83–7.80 (d, J=12.0 Hz, 2H), 7.61–7.59 (d, J=8.0 Hz, 2H), 7.49–7.47 (d, J=8.0 Hz, 2H), 6.51–6.45 (m, 1H), 5.25–5.22 (d, J=12.0 Hz, 1H), 5.00–4.94 (dd, J=16.0, 12 Hz, 1H), 4.90–4.87 (d, J=12.0 Hz, 1H), 3.58 (s, 3H), 3.34–3.31 (d, J=12.0 Hz, 6H), 3.14–3.11 (d, J=12.0 Hz, 1H), 1.68–1.60 (m, 1H), 1.52–1.46 (m, 1H), 1.35–1.28 (m, 1H), 1.06–1.04 (d, J=8.0 Hz, 3H), 0.98–0.96 (d, J=8.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  182.21, 146.26, 144.10, 134.60, 132.60, 125.84, 125.46, 123.77, 66.68, 53.51, 50.27, 49.61, 41.50, 33.29, 24.54, 23.04, 22.98; HRMS (ESI): calcd for [M–Br]<sup>+</sup> (C<sub>23</sub>H<sub>32</sub>BrN<sub>4</sub>O<sub>2</sub>S) requires 507.1429, found 507.1427.

#### 4.4. General procedure for the asymmetric aza-Henry reaction

To a stirred solution of the corresponding amidosulfone (0.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (8.0 mL) were added nitroalkane (1.0 mmol) and catalyst **1** at –30 °C under argon. The reaction mixture was vigorously stirred and then grounded KOH (1.0 mmol) was added. After 8 h (monitored by TLC), 10 mL of satd aq NaHCO<sub>3</sub> was added and the mixture was allowed to warm to ambient temperature and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic extracts were concentrated under reduced pressure using a rotary evaporator and the residue was purified by silica gel chromatography (hexane/EtOAc as the eluent) to afford the desired products **3**.

**4.4.1. (S)-tert-Butyl 2-nitro-1-phenylethylcarbamate (3a).** Yield: 94%; White solid;  $[\alpha]_D^{25}$  +20.5 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.40–7.26 (m, 5H), 5.37 (br, 1H), 5.27 (br, 1H), 4.85 (br, 1H), 4.73–4.68 (m, 1H), 1.44 (s, 9H); Enantiomeric excess: 92%, determined by HPLC (Chiralpak PC-II column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =17.9 min;  $t_{\text{minor}}$ =15.5 min).

**4.4.2. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3b).** Yield: 80%; White solid;  $[\alpha]_D^{25}$  +19.8 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.31–7.29 (d, J=5.2 Hz, 1H), 7.28–7.27 (d, J=8.0 Hz, 1H), 7.10–7.05 (t, J=8.4 Hz, 3H), 5.34 (br, 1H), 5.27 (br, 1H), 4.84 (br, 1H), 4.71–4.66 (m, 1H), 1.44 (s, 9H); Enantiomeric excess: 89%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =17.4 min;  $t_{\text{minor}}$ =23.5 min).

**4.4.3. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3c).** Yield: 92%; White solid;  $[\alpha]_D^{25}$  +30.8 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.18 (s, 4H), 5.33 (br, 1H), 5.21 (br, 1H), 4.83 (br, 1H), 4.70–4.66 (m, 1H), 2.34 (s, 1H), 1.44 (s, 9H); Enantiomeric excess: 93%, determined by HPLC (Chiralpak PC-II column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =17.4 min;  $t_{\text{minor}}$ =15.2 min).

**4.4.4. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3d).** Yield: 85%; White solid;  $[\alpha]_D^{25}$  +12.3 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.66–7.64 (d, J=8.0 Hz, 2H), 7.46–7.44 (d, J=8.0 Hz, 2H), 5.47 (br, 2H), 4.89 (br, 1H), 4.75 (m, 1H), 1.44 (s, 9H); Enantiomeric excess: 89%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =14.1 min;  $t_{\text{minor}}$ =23.2 min).

**4.4.5. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3e).** Yield: 90%; White solid;  $[\alpha]_D^{25}$  +37.2 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)

$\delta$  7.23–7.21 (d, J=8.0 Hz, 2H), 6.91–6.89 (d, J=8.0 Hz, 2H), 5.30 (br, 1H), 5.16 (br, 1H), 4.85 (br, 1H), 4.69–4.64 (m, 1H), 3.80 (s, 3H), 1.44 (s, 9H); Enantiomeric excess: 94%, determined by HPLC (Chiralpak OD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =46.6 min;  $t_{\text{minor}}$ =40.9 min).

**4.4.6. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3f).** Yield: 90%; White solid;  $[\alpha]_D^{25}$  +39.2 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.32–7.28 (t, J=8.0 Hz, 1H), 6.87–6.83 (m, 3H), 5.34 (br, 1H), 5.25 (br, 1H), 4.83 (br, 1H), 4.71–4.67 (m, 1H), 3.81 (s, 3H), 1.44 (s, 9H); Enantiomeric excess: 96%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =27.9 min;  $t_{\text{minor}}$ =42.1 min).

**4.4.7. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3g).** Yield: 98%; White solid;  $[\alpha]_D^{25}$  +48.9 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.33–7.29 (t, J=8.0 Hz, 1H), 7.24 (br, 1H), 6.97–6.93 (t, J=7.6 Hz, 1H), 6.92–6.90 (d, J=8.0 Hz, 1H), 5.71 (br, 1H), 5.56 (br, 1H), 4.79 (m, 1H), 4.69 (m, 1H), 3.90 (s, 3H), 1.44 (s, 9H); Enantiomeric excess: 94%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =23.4 min;  $t_{\text{minor}}$ =22.0 min).

**4.4.8. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3h).** Yield: 99%; White solid;  $[\alpha]_D^{25}$  +11.0 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.13–8.11 (d, J=8.0 Hz, 1H), 7.91–7.89 (d, J=8.0 Hz, 1H), 7.86–7.83 (m, 1H), 7.63–7.59 (t, J=7.2 Hz, 1H), 7.56–7.54 (d, J=8.0 Hz, 1H), 7.46–7.44 (m, 2H), 6.28 (br, 1H), 5.36 (br, 1H), 4.89 (br, 1H), 1.43 (s, 9H); Enantiomeric excess: 91%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =24.2 min;  $t_{\text{minor}}$ =44.1 min).

**4.4.9. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3i).** Yield: 80%; White solid;  $[\alpha]_D^{25}$  +37.9 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.38 (br, 1H), 6.35 (m, 1H), 6.32 (m, 1H), 5.46 (br, 1H), 5.27 (br, 1H), 4.85 (br, 1H), 4.75–4.71 (m, 1H), 1.46 (s, 9H); Enantiomeric excess: 88%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =14.5 min;  $t_{\text{minor}}$ =13.5 min).

**4.4.10. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3j).** Yield: 98%; White solid;  $[\alpha]_D^{25}$  –29.9 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.31–7.28 (t, J=8.0 Hz, 2H), 7.23–7.21 (d, J=8.0 Hz, 1H), 7.18–7.16 (d, J=8.0 Hz, 2H), 4.87 (br, 1H), 4.54 (br, 2H), 4.10 (m, 1H), 2.77–2.65 (m, 2H), 1.93–1.89 (m, 2H), 1.46 (s, 9H); Enantiomeric excess: 68%, determined by HPLC (Chiralpak PC-II column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =7.8 min;  $t_{\text{minor}}$ =8.4 min).

**4.4.11. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3k).** Yield: 99%; White solid;  $[\alpha]_D^{25}$  +19.1 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.36–7.33 (m, 3H), 7.24–7.22 (m, 2H), 5.30 (br, 1H), 5.19–5.17 (m, 1H), 4.93 (br, 1H), 1.54–1.52 (d, J=8.0 Hz, 3H), 1.43 (s, 9H); Enantiomeric excess: 96%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =15.6 min;  $t_{\text{minor}}$ =21.4 min).

**4.4.12. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3l).** Yield: 99%; White solid;  $[\alpha]_D^{25}$  +33.1 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.36–7.32 (m, 3H), 7.24–7.22 (m, 2H), 5.14 (br, 2H), 4.74 (br, 1H), 2.10–2.00 (m, 1H), 1.91–1.85 (m, 1H), 1.43 (s, 9H), 1.00–0.97 (t, J=7.2 Hz, 3H); Enantiomeric excess: 89%, determined by HPLC (Chiralpak AS-H column, hexane/*i*-PrOH 90:10,  $\lambda$ =214 nm, flow rate 0.7 mL/min;  $t_{\text{major}}$ =83.4 min;  $t_{\text{minor}}$ =5.3 min).

**4.4.13. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3m).** Yield: 99%; White solid;  $[\alpha]_D^{25}$  +23.0 (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.23–7.20 (br, 2H), 7.07–7.03 (t, J=8.8 Hz, 2H), 5.36 (br, 1H), 5.16–5.12 (m, 1H), 4.90 (br, 1H), 1.54–1.52 (d, J=8.0 Hz, 3H), 1.43 (s, 9H); Enantiomeric excess: 99%, determined by HPLC (Chiralpak AD-H column,

hexane/*i*-PrOH 90:10,  $\lambda=214$  nm, flow rate 0.7 mL/min;  $t_{\text{major}}=13.4$  min;  $t_{\text{minor}}=15.4$  min).

**4.4.14. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3n).** Yield: 99%; White solid;  $[\alpha]_{\text{D}}^{25} +36.8$  (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.16–7.13 (d,  $J=8.0$  Hz, 2H), 6.88–6.86 (d,  $J=8.0$  Hz, 2H), 5.25 (br, 1H), 5.12–5.08 (br, 1H), 4.90 (br, 1H), 3.76 (s, 3H), 1.53–1.52 (d,  $J=4.0$  Hz, 3H), 1.43 (s, 9H); Enantiomeric excess: 97%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda=214$  nm, flow rate 0.7 mL/min;  $t_{\text{major}}=19.5$  min;  $t_{\text{minor}}=21.4$  min).

**4.4.15. (S)-tert-Butyl 1-(4-fluoropenyl)-2-nitrothylcarbamate (3o).** Yield: 99%; White solid;  $[\alpha]_{\text{D}}^{25} 22.3$  (c +0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.29–7.25 (t,  $J=8.0$  Hz, 1H), 6.87–6.84 (dd,  $J=8.0, 1.2$  Hz, 1H), 6.82–6.80 (d,  $J=8.0$  Hz, 1H), 6.76 (br, 1H), 5.26 (br, 1H), 5.20–5.16 (m, 1H), 4.90 (br, 1H), 3.80 (s, 3H), 1.54–1.52 (d,  $J=8.0$  Hz, 3H), 1.43 (s, 9H); Enantiomeric excess: 99.5%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 80:20,  $\lambda=214$  nm, flow rate 0.7 mL/min;  $t_{\text{major}}=12.0$  min;  $t_{\text{minor}}=7.8$  min).

## 4.5. Preparation of 6

The method of Barber was employed: a mixture of **3k** (0.4 mmol) in toluene was degassed and flushed with nitrogen several times before AIBN (0.08 mmol) and (Bu)<sub>3</sub>SnH (0.8 mmol) were added, followed by heating at reflux for 4 h. The reaction mixture was allowed to cool to room temperature and then directly purified by flash column chromatography (hexane/EtOAc as the eluent) to afford the desired product **6** as a colourless oil. On standing the product crystallized in to a white solid.

**4.5.1. (R)-tert-Butyl 1-phenylpropylcarbamate (6).** Yield: 80%; White solid;  $[\alpha]_{\text{D}}^{25} +72.9$  (c 0.5, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.34–7.22 (m, 5H), 4.81 (br, 1H), 4.52 (br, 1H), 1.78–1.76 (m, 2H), 1.41 (s, 9H), 0.90–0.87 (t,  $J=7.4$  Hz, 3H); Enantiomeric excess: 87%, determined by HPLC (Chiralpak AD-H column, hexane/*i*-PrOH 90:10,  $\lambda=214$  nm, flow rate 0.7 mL/min;  $t_{\text{major}}=7.8$  min;  $t_{\text{minor}}=8.4$  min).

## 4.6. Preparation of 5

According to the reported methods:<sup>17</sup> a solution of the nitro compound **1a** (5.0 mmol, 1.3 g, 89% ee), sodium nitrite (700 mg, 10 mmol) and acetic acid (50 mmol) in DMSO (30 mL) was heated at 40 °C for 1 day. After cooling to room temperature, 1.0 M HCl (50 mL) was added and the aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub>, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude product was purified by flash column chromatography, followed by treatment with TFA in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) with stirring at room temperature for 24 h. Then satd aq Na<sub>2</sub>CO<sub>3</sub> was added to adjust the pH value to around 9, followed by extraction with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude product was added to a suspension of NaBH<sub>4</sub> (3 equiv) in THF (10 mL), followed by dropwise addition of a solution of I<sub>2</sub> in THF (5 mL) over 1 h at 0 °C. When finished, the solution was refluxed for 18 h before being cooled to room temperature. Methanol (10 mL) and aqueous NaOH (20%, 10 mL) were added, and the resulting mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude product was mixed with Et<sub>3</sub>N (2.5 equiv), CS<sub>2</sub> (3 equiv) in 10 mL of DMSO and the mixture was warmed to 100 °C with irradiation at 40 W of power for 2 h. Then water was added and the resulting mixture was extracted with EtOAc, dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and purified by silica gel chromatography to afford **5**.

**4.6.1. (S)-4-Phenylthiazolidine-2-thione (5).** Yield: 56%; White solid;  $[\alpha]_{\text{D}}^{25} +182.9$ , c 0.5 in CHCl<sub>3</sub> ( $[\alpha]_{\text{D}}^{25}(\text{Lit.})$  207.0, c 1.0 in CHCl<sub>3</sub> for

optical pure); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.61 (br, 1H), 7.42–7.37 (m, 5H), 5.33–5.29 (t,  $J=8.0$  Hz, 1H), 3.87–3.82 (dd,  $J=11, 8.0$  Hz, 1H), 3.53–3.48 (dd,  $J=11.0, 8.0$  Hz, 1H).

## Acknowledgements

This work was financially supported by National Basic Research Program of China (973 Program, 2010CB833300), the National Natural Science Foundation of China (Nos. 21032006, 203900502, 20532040, 21290180), Science and Technology Commission of Shanghai Municipality (11XD1406400) and Excellent Young Scholars Foundation of National Natural Science Foundation of China (20525208).

## Supplementary data

Supplementary data related to this article can be found online at <http://dx.doi.org/10.1016/j.tet.2013.04.079>.

## References and notes

- For selected recent reviews: (a) Davie, E. A. C.; Mennen, S. M.; Xu, Y.; Miller, S. J. *Chem. Rev.* **2007**, *107*, 5759–5812; (b) Xu, L.-W.; Lu, Y. *Org. Biomol. Chem.* **2008**, *6*, 2047–2053; (c) Paradowska, J.; Stodulski, M.; Mlynarski, J. *Angew. Chem., Int. Ed.* **2009**, *48*, 4288–4297; (d) Xu, L.-W.; Luo, J.; Lu, Y. *Chem. Commun.* **2009**, 1807–1821; (e) Xu, L.-W.; Li, L.; Shi, Z.-H. *Adv. Synth. Catal.* **2010**, *352*, 243–279; (f) Chai, Z.; Zhao, G. *Catal. Sci. Technol.* **2012**, *2*, 29–41.
- For selected recent reviews: (a) Grondal, C.; Jeanty, M.; Enders, D. *Nat. Chem.* **2010**, *2*, 167–178; (b) Albrecht, L.; Jiang, H.; Jørgensen, K. A. *Angew. Chem., Int. Ed.* **2011**, *50*, 8492–8509; (c) Piovesana, S.; Schietroma, D. M. S.; Bella, M. *Angew. Chem., Int. Ed.* **2011**, *50*, 6216–6232.
- For selected recent examples about primary–secondary diamines: (a) Yang, Y.-Q.; Zhao, G. *Chem.—Eur. J.* **2008**, *14*, 10888–10891; (b) Hong, L.; Sun, W.; Liu, C.; Wang, L.; Wong, K.; Wang, R. *Chem.—Eur. J.* **2009**, *15*, 11105–11108; (c) Liu, J.; Yang, Z.; Liu, X.; Wang, Z.; Liu, Y.; Bai, S.; Lin, L.; Feng, X. *Org. Biomol. Chem.* **2009**, *7*, 4120–4127; (d) Yang, Y.-Q.; Chai, Z.; Wang, H.-F.; Chen, X.-K.; Cui, H.-F.; Zheng, C.-W.; Xiao, H.; Li, P.; Zhao, G. *Chem.—Eur. J.* **2009**, *15*, 13295–13298; (e) Cui, H.-F.; Yang, Y.-Q.; Chai, Z.; Li, P.; Zheng, C.-W.; Zhu, S.-Z.; Zhao, G. *J. Org. Chem.* **2010**, *75*, 117–122; (f) Yang, Y.-Q.; Chen, X.-K.; Xiao, H.; Liu, W.; Zhao, G. *Chem. Commun.* **2010**, 4130–4132; (g) Lu, Y.; Zheng, C. W.; Yang, Y.-Q.; Zhao, G.; Zou, G. *Adv. Synth. Catal.* **2011**, *353*, 3129–3133; (h) Sun, W.; Hong, L.; Wang, R. *Chem.—Eur. J.* **2011**, *17*, 6030–6033.
- For selected recent examples about tertiary amine–thioureas: (a) Andres, J. M.; Manzano, R.; Pedrosa, R. *Chem.—Eur. J.* **2008**, *14*, 5116–5119; (b) Pu, X.; Li, P.; Peng, F.; Li, X.; Zhang, H.; Shao, Z. *Eur. J. Org. Chem.* **2009**, 4622–4626; (c) Zhao, S.-L.; Zheng, C.-W.; Wang, H.-F.; Zhao, G. *Adv. Synth. Catal.* **2009**, *351*, 2811–2816; (d) Zhao, S.-L.; Zheng, C.-W.; Zhao, G. *Tetrahedron: Asymmetry* **2009**, *20*, 1046–1051; (e) Chen, X.-K.; Zheng, C.-W.; Zhao, S.-L.; Chai, Z.; Yang, Y.-Q.; Zhao, G.; Cao, W.-G. *Adv. Synth. Catal.* **2010**, *352*, 1648–1652; (f) Manzano, R.; Andres, J. M.; Muruzabal, M. D.; Pedrosa, R. *Adv. Synth. Catal.* **2010**, *352*, 3364–3372; (g) Manzano, R.; Andres, J. M.; Muruzabal, M.-D.; Pedrosa, R. *J. Org. Chem.* **2010**, *75*, 5417–5420; (h) Pu, X.-W.; Peng, F.-Z.; Zhang, H.-B.; Shao, Z.-H. *Tetrahedron* **2010**, *66*, 3655–3661; (i) Li, P.; Zhao, G.; Zhu, S. *Chin. J. Chem.* **2011**, *29*, 2749–2758; (j) Li, X.-J.; Peng, F.-Z.; Li, X.; Wu, W.-T.; Sun, Z.-W.; Li, Y.-M.; Zhang, S.-X.; Shao, Z.-H. *Chem.—Asian J.* **2011**, *6*, 220–225; (k) Manzano, R.; Andres, J. M.; Alvarez, R.; Muruzabal, M. D.; de Lera, A. R.; Pedrosa, R. *Chem.—Eur. J.* **2011**, *17*, 5931–5938; (l) Wang, H.-F.; Li, P.; Cui, H.-F.; Wang, X.-W.; Zhang, J.-K.; Liu, W.; Zhao, G. *Tetrahedron* **2011**, *67*, 1774–1780; (m) Ye, Z.; Zhao, G. *Chimia* **2011**, *65*, 902–908; (n) Joerres, M.; Schiffrers, I.; Atodiresei, I.; Bolm, C. *Org. Lett.* **2012**, *14*, 4518–4521; (o) Li, G.-X.; Qu, J. *Chem. Commun.* **2012**, 5518–5520.
- For selected recent examples about aminophosphines: (a) Cowen, B. J.; Miller, S. J. *J. Am. Chem. Soc.* **2007**, *129*, 10988–10989; (b) Xiao, H.; Chai, Z.; Zheng, C.-W.; Yang, Y.-Q.; Liu, W.; Zhang, J.-K.; Zhao, G. *Angew. Chem., Int. Ed.* **2010**, *49*, 4467–4470; (c) Zhu, Q.; Lu, Y. *Angew. Chem., Int. Ed.* **2010**, *49*, 7753–7756; (d) Gong, J.-J.; Li, T.-Z.; Pan, K.; Wu, X.-Y. *Chem. Commun.* **2011**, 1491–1493; (e) Han, X.; Wang, Y.; Zhong, F.; Lu, Y. *Org. Biomol. Chem.* **2011**, *9*, 6734–6740; (f) Han, X.; Wang, Y.; Zhong, F.; Lu, Y. *J. Am. Chem. Soc.* **2011**, *133*, 1726–1729; (g) Zhong, F.; Han, X.; Wang, Y.; Lu, Y. *Angew. Chem., Int. Ed.* **2011**, *50*, 7837–7841; (h) Zhong, F.; Wang, Y.; Han, X.; Huang, K.-W.; Lu, Y. *Org. Lett.* **2011**, *13*, 1310–1313; (i) Jin, Z.; Yang, R.; Du, Y.; Tiwari, B.; Ganguly, R.; Chi, Y. R. *Org. Lett.* **2012**, *14*, 3226–3229; (j) Shi, Z.; Yu, P.; Loh, T.-P.; Zhong, G. *Angew. Chem., Int. Ed.* **2012**, *51*, 7825–7829; (k) Wang, D.; Wei, Y.; Shi, M. *Chem. Commun.* **2012**, 2764–2766; (l) Zhong, F.; Chen, G.-Y.; Han, X.; Yao, W.; Lu, Y. *Org. Lett.* **2012**, *14*, 3764–3767; (m) Zhong, F.; Han, X.; Wang, Y.; Lu, Y. *Chem. Sci.* **2012**, *3*, 1231–1234.
- For representative examples: (a) O'Donnell, M. J. *Acc. Chem. Res.* **2004**, *37*, 506–517; (b) Lygo, B.; Andrews, B. I. *Acc. Chem. Res.* **2004**, *37*, 518–525; (c) Ooi, T.; Maruoka, K. *Acc. Chem. Res.* **2004**, *37*, 526–533; (d) Hashimoto, T.; Maruoka, K. *Chem. Rev.* **2007**, *107*, 5656–5682; (e) Ooi, T.; Maruoka, K. *Angew. Chem., Int. Ed.* **2007**, *46*, 4222–4266; (f) Gomez Arayars, R.; Carretero, J. C. *Chem. Soc. Rev.* **2009**, *38*, 1940–1948; (g) O'Donnell, M. J.; Bennett, W. D.; Wu, S. J. *Am. Chem.*

- Soc. **1989**, *111*, 2353–2355; (h) Corey, E. J.; Xu, F.; Noe, M. C. *J. Am. Chem. Soc.* **1997**, *119*, 12414–12415; (i) Ooi, T.; Kameda, M.; Maruoka, K. *J. Am. Chem. Soc.* **1999**, *121*, 6519–6520; (j) Ooi, T.; Takeuchi, M.; Kameda, M.; Maruoka, K. *J. Am. Chem. Soc.* **2000**, *122*, 5228–5229; (k) Kita, T.; Georgieva, A.; Hashimoto, Y.; Nakata, T.; Nagasawa, K. *Angew. Chem., Int. Ed.* **2002**, *41*, 2832–2834.
7. (a) Xiao, H.; Chai, Z.; Wang, H.-F.; Wang, X.-W.; Cao, D.-D.; Liu, W.; Lu, Y.-P.; Yang, Y.-Q.; Zhao, G. *Chem.—Eur. J.* **2011**, *17*, 10561–10564; (b) Cui, H.-F.; Li, P.; Wang, X.-W.; Zhu, S.-Z.; Zhao, G. *J. Fluorine Chem.* **2012**, *133*, 120–126; (c) Xiao, H.; Chai, Z.; Cao, D.-D.; Wang, H.; Chen, J.; Zhao, G. *Org. Biomol. Chem.* **2012**, *10*, 3195–3201.
8. For selected examples about H-bonding: (a) Takemoto, Y. *Org. Biomol. Chem.* **2005**, *3*, 4299–4306; (b) Taylor, M. S.; Jacobsen, E. N. *Angew. Chem., Int. Ed.* **2006**, *45*, 1520–1543; (c) Doyle, A. G.; Jacobsen, E. N. *Chem. Rev.* **2007**, *107*, 5713–5743.
9. Chiral phase-transfer catalyst about H-bonding: (a) Ooi, T.; Ohara, D.; Tamura, M.; Maruoka, K. *J. Am. Chem. Soc.* **2004**, *126*, 6844–6845; (b) Berkessel, A.; Guixa, M.; Schmidt, F.; Neudoerfl, J. M.; Lex, J. *Chem.—Eur. J.* **2007**, *13*, 4483–4498; (c) Gomez-Bengoa, E.; Linden, A.; Lopez, R.; Mugica-Mendiola, I.; Oiarbide, M.; Palomo, C. *J. Am. Chem. Soc.* **2008**, *130*, 7955–7966; (d) Liu, Y.; Provencher, B. A.; Bartelson, K. J.; Deng, L. *Chem. Sci.* **2011**, *2*, 1301–1304; (e) Provencher, B. A.; Bartelson, K. J.; Liu, Y.; Foxman, B. M.; Deng, L. *Angew. Chem., Int. Ed.* **2011**, *50*, 10565–10569; (f) Johnson, K. M.; Rattley, M. S.; Sladojevich, F.; Barber, D. M.; Nunez, M. G.; Goldys, A. M.; Dixon, D. J. *Org. Lett.* **2012**, *14*, 2492–2495.
10. (a) Ohmatsu, K.; Kiyokawa, M.; Ooi, T. *J. Am. Chem. Soc.* **2011**, *133*, 1307–1309; (b) Ohmatsu, K.; Hamajima, Y.; Ooi, T. *J. Am. Chem. Soc.* **2012**, *134*, 8794–8797.
11. See the preparations of the catalysts for more details.
12. (a) Lucet, D.; Le Gall, T.; Mioskowski, C. *Angew. Chem., Int. Ed.* **1998**, *37*, 2580–2627; (b) Kotti, S.; Timmons, C.; Li, G. G. *Chem. Biol. Drug Des.* **2006**, *67*, 101–114; (c) Marques-Lopez, E.; Merino, P.; Tejero, T.; Herrera, R. P. *Eur. J. Org. Chem.* **2009**, 2401–2420.
13. (a) Fini, F.; Sgarzani, V.; Pettersen, D.; Herrera, R. P.; Bernardi, L.; Ricci, A. *Angew. Chem., Int. Ed.* **2005**, *44*, 7975–7978; (b) Kumaraswamy, G.; Pitchaiah, A. *Tetrahedron* **2011**, *67*, 2536–2541.
14. Chen, N.; Jia, W.; Xu, J. *Eur. J. Org. Chem.* **2009**, 5841–5846.
15. Barber, D. J.; Sangane, H. J.; Dixon, D. J. *Org. Lett.* **2012**, *14*, 5290–5293.
16. Juaristi, E.; Leon-Romo, J. L.; Reyes, A.; Escalante, J. *Tetrahedron: Asymmetry* **1999**, *10*, 2441–2495.
17. (a) Palomo, C.; Oiarbide, M.; Halder, R.; Laso, A.; Lopez, R. *Angew. Chem., Int. Ed.* **2006**, *45*, 117–120; (b) Morales-Nava, R.; Fernandez-Zertuche, M.; Ordonez, M. *Molecules* **2011**, *16*, 8803–8814.